Investment Rating - The investment rating for the company is "Accumulate" (maintained) [1] Core Views - The company reported a revenue of 1.152 billion yuan for 2024, representing a year-on-year increase of 32.64%. The net profit attributable to shareholders was 246 million yuan, up 27.26% year-on-year [4][6] - The company has successfully launched new production capacities, which, along with increasing downstream demand, has significantly supported revenue and profit growth [6][7] - The D-alloheptulose product is expected to be approved for market entry, which could drive additional revenue growth for the company [8][10] - The company is expanding its production capacity in Thailand, which is anticipated to lower production costs and enhance profitability [9][10] Summary by Sections Financial Performance - In Q4 2024, the company achieved a revenue of 331 million yuan, a year-on-year increase of 54.46% and a quarter-on-quarter increase of 14.61%. The net profit attributable to shareholders was 63 million yuan, up 21.97% year-on-year [4] - For Q1 2025, the company reported a revenue of 313 million yuan, a year-on-year increase of 24.27%, while the net profit attributable to shareholders was 81 million yuan, up 52.06% year-on-year [5] Production Capacity and Sales - The company successfully launched projects for 30,000 tons of dietary fiber, 10,000 tons of crystalline fructose, and 5,000 tons of D-alloheptulose, which have contributed to increased sales and revenue [7] - The main products, including prebiotics, dietary fibers, and healthy sweeteners, generated revenues of 322 million, 624 million, and 156 million yuan respectively, with year-on-year growth rates of 25.43%, 40.42%, and 13.85% [6] Market and Policy Environment - The company is well-positioned to benefit from favorable policies aimed at promoting healthy consumption, which aligns with its diverse product offerings [10] - The anticipated approval of D-alloheptulose as a new food ingredient is expected to significantly boost domestic demand and revenue [8][10] Future Projections - The company forecasts net profits attributable to shareholders of 338 million, 412 million, and 537 million yuan for 2025, 2026, and 2027 respectively, with corresponding P/E ratios of 20, 16, and 13 [11]

Investment Rating - The investment rating for the company is "Outperform the Market" [4][11][28] Core Views - The company achieved a net profit attributable to shareholders of 246 million yuan in 2024, representing a year-on-year growth of 27%. In the first quarter of 2025, the net profit reached 81.4 million yuan, up 52% year-on-year [1][13] - The company’s revenue for 2024 was 1.152 billion yuan, a 32.64% increase compared to the previous year. In Q1 2025, revenue was 313 million yuan, growing 24.27% year-on-year [1][13] - The company is experiencing rapid growth in its dietary fiber and health sweetener segments, particularly with the increasing demand for resistant dextrin and polydextrose in the food and beverage industry [2][21] - The company is actively expanding its production capacity through projects such as the "Functional Sugar Drying Expansion Project" and the "Thailand Health Project," which are expected to enhance profitability in the future [3][26] Financial Performance Summary - In 2024, the company’s gross profit margin was 33.65%, an increase of 0.92 percentage points year-on-year, while the net profit margin was 21.33%, a decrease of 0.90 percentage points [1][13] - For Q1 2025, the gross profit margin improved to 39.74%, up 5.99 percentage points year-on-year, and the net profit margin increased to 25.99%, up 4.75 percentage points year-on-year [1][13] - The company’s revenue projections for 2025-2027 are 1.526 billion yuan, 1.829 billion yuan, and 2.140 billion yuan, respectively, with net profits expected to be 346 million yuan, 431 million yuan, and 503 million yuan [12][28] Business Segments Summary - The company’s main business segments include prebiotics, dietary fibers, health sweeteners, and other starch sugars. In 2024, the prebiotic segment generated 322 million yuan in revenue, a 25.43% increase, while the dietary fiber segment saw revenue of 624 million yuan, up 40.42% [2][21] - The health sweetener segment generated 156 million yuan in revenue, a 13.85% increase, with the contribution of allulose rising to 14.12% of total revenue, marking it as a significant source of income [2][21] - In Q1 2025, the prebiotic segment revenue was 85.8 million yuan, up 17.27%, while the dietary fiber segment revenue was 170 million yuan, up 25.40%. The allulose segment revenue surged to 49.8 million yuan, a remarkable increase of 105.31% [2][21] Future Growth Drivers - The company is investing in a new production base in Thailand, which is expected to enhance its brand, technology development, and market expansion capabilities, ultimately improving profitability and competitiveness [4][26] - The ongoing approval process for allulose in China and the steady growth of the overseas market are anticipated to further boost the company’s revenue and market presence [9][27]

Core Viewpoint - The company reported strong financial performance for 2024 and Q1 2025, with significant revenue and profit growth driven by product expansion and capacity enhancements [1][3]. Financial Performance - In 2024, the company achieved revenue of 1.152 billion yuan, a year-on-year increase of 32.64%, and a net profit attributable to shareholders of 246 million yuan, up 27.26% [1]. - For Q1 2025, revenue reached 313 million yuan, reflecting a year-on-year growth of 24.27%, with a net profit of 81 million yuan, marking a substantial increase of 52.06% [1]. Product Revenue Breakdown - In 2024, the dietary fiber series generated revenue of 624 million yuan, up 40.42%, while the prebiotic series brought in 322 million yuan, a 25.43% increase. The health sweeteners series earned 156 million yuan, growing by 13.85%. However, other starch sugars (alcohols) saw a decline, with revenue of 4 million yuan, down 72.48% [1]. - For Q1 2025, the dietary fiber series revenue was 170 million yuan, up 25.4%, the prebiotic series earned 86 million yuan, a 17.3% increase, and the health sweeteners series saw a remarkable growth of 105.3%, generating 50 million yuan. Other starch sugars (alcohols) achieved 2 million yuan, up 10.3% [2]. Profitability and Cost Management - The company's gross margin for 2024 was 33.65%, with a net profit margin of 21.33%. In Q1 2025, these figures improved to 39.74% and 25.99%, respectively, indicating a significant enhancement in profitability [3]. - The increase in gross margin is attributed to the production chain extension from new projects, a decrease in raw material prices, and the realization of scale efficiencies [3]. Capacity Expansion Projects - The company is actively constructing two major capacity enhancement projects: the functional sugar drying expansion project, expected to be completed by 2025-2026, and the Thailand health food raw material smart factory project, anticipated to start construction in Q2-Q3 2025 [4]. - The Thailand project aims to produce various sugar products, which will help reduce production costs and mitigate potential trade risks due to tariffs [4]. Market Opportunities - The domestic approval of D-allohexose as a new food raw material is expected soon, providing a significant market opportunity for the company's health sweeteners [5]. - The "Healthy China Action" initiative includes functional sweeteners in its support directory, with over 500 million yuan in subsidies planned for 2025, further bolstering the market for alternative sweeteners [5]. Profit Forecast - The company is projected to achieve net profits of 341 million yuan, 457 million yuan, and 624 million yuan for 2025-2027, representing year-on-year growth rates of 39%, 34%, and 37%, respectively [5].

Core Viewpoint - Shandong Bailong Chuangyuan Biotechnology Co., Ltd. reported strong financial performance for 2024, with total revenue of 1.152 billion yuan, a year-on-year increase of 32.64%, and a net profit of 246 million yuan, up 27.26% [1] Group 1: Financial Performance - In 2024, the company achieved total revenue of 1.152 billion yuan, a 32.64% increase year-on-year [1] - The net profit attributable to shareholders was 246 million yuan, reflecting a 27.26% growth [1] - For Q1 2025, the company reported revenue of 313 million yuan, a 24.27% increase year-on-year, and a net profit of 81.42 million yuan, up 52.06% [3] Group 2: Product Segments - The company's main product lines include prebiotics, dietary fibers, health sweeteners, and other starch sugar products [1] - Revenue from prebiotics and dietary fibers reached 322 million yuan and 624 million yuan, with year-on-year growth of 25.43% and 40.42%, respectively [1] - Health sweeteners generated 156 million yuan in revenue, a 13.85% increase, accounting for 14.12% of total revenue [1] Group 3: Expansion and R&D - The company is expanding production capacity with new projects, including a 30,000-ton soluble dietary fiber project and a 15,000-ton crystallized sugar project [2] - R&D expenses for 2024 reached 44.4622 million yuan, a significant increase of 36%, with an R&D expense ratio of 3.86% [2] - The gross profit margin improved to 34.35%, up 1.32 percentage points from the previous year, indicating strong profitability [2] Group 4: Global Market Presence - In 2024, the company's overseas revenue reached 698 million yuan, a 58.42% increase, accounting for 63.08% of main business revenue [2] - The company has expanded its market presence across Asia, Europe, and North America, capitalizing on the growing demand for health foods and functional sweeteners [2]

Financial Performance - The company achieved total operating revenue of CNY 1,151,652,269.49, representing a year-on-year growth of 32.64%[22]. - Net profit attributable to shareholders reached CNY 245,598,458.46, an increase of 27.26% compared to the previous year[22]. - The net profit after deducting non-recurring gains and losses was CNY 231,338,948.07, up 31.72% year-on-year[22]. - Cash flow from operating activities amounted to CNY 300,892,601.89, reflecting a significant growth of 54.59%[22]. - The company's total assets increased to CNY 2,013,504,803.94, a year-on-year growth of 14.78%[23]. - Shareholders' equity rose to CNY 1,679,237,143.49, marking an 11.37% increase from the previous year[23]. - Basic earnings per share were CNY 0.76, up 26.67% compared to CNY 0.60 in 2023[21]. - The company's operating costs increased to CNY 764,114,719.26, up 30.82% compared to the previous year[83]. - Research and development expenses rose to CNY 44,462,205.68, marking a 36.56% increase year-on-year[83]. Dividend and Share Capital - The company plans to distribute a cash dividend of RMB 1.40 per 10 shares, totaling RMB 45.23 million for the year, which represents 24.99% of the net profit attributable to shareholders[5]. - The total share capital after the proposed capital reserve transfer will increase from 323,086,400 shares to 420,012,320 shares[5]. - The average cash dividend payout ratio over the last three years is 76.97%, with a total cash dividend of RMB 151.21 million during that period[152]. Product Development and Innovation - The company has successfully launched two major projects: a soluble dietary fiber project with an annual production capacity of 30,000 tons and a crystallized sugar project with a capacity of 15,000 tons, significantly improving production capacity and profitability[31]. - The company has successfully developed and mass-produced isomaltulose and crystallized fructose, enhancing its product structure and competitive edge in the market[36]. - The company has obtained 6 authorized invention patents in 2024 and received various certifications, enhancing its innovation capabilities and market competitiveness[40]. - The company aims to develop 5-6 new product specifications annually and has launched products like sugar-free resistant dextrin and high DE resistant dextrin in 2023[77]. Market Trends and Projections - In 2023, global prebiotic production reached 279,200 tons, generating sales of $1.278 billion, with a projected compound annual growth rate (CAGR) of 6.75% from 2023 to 2030[46]. - By 2030, global prebiotic production is expected to reach 441,200 tons, with sales projected to hit $2.279 billion, reflecting a CAGR of 8.62%[46]. - The global dietary fiber market sales reached $5.14 billion in 2023, with a compound annual growth rate (CAGR) of 6.58% from 2019 to 2023[54]. - The demand for high-fiber staple foods is growing at an annual rate of over 10% in developed countries, driven by health concerns related to chronic diseases[53]. Corporate Governance - The governance structure includes a board of nine directors, with three independent directors, ensuring compliance with legal and regulatory requirements[116]. - The company has maintained independence from its controlling shareholders in terms of personnel, business, assets, and finance, ensuring no interference in operational decisions[119]. - The company plans to continue enhancing its internal control systems in compliance with relevant laws and regulations to promote healthy development[118]. - The company has established specialized committees under the board, including audit, nomination, remuneration, and strategic committees[135]. Environmental Responsibility - The company has been recognized as a national "Green Factory" and a "Waste-Free Factory" in Shandong Province[166]. - The company has implemented a carbon reduction measure, achieving a reduction of 2,290 tons of CO2 equivalent emissions[166]. - The company has established an environmental self-monitoring plan to oversee pollutant emissions and ensure compliance[163]. - The company invested 16.31 million yuan in environmental protection during the reporting period[157]. Strategic Initiatives - The company is focused on improving its corporate governance and operational independence to safeguard shareholder interests[119]. - The management plans to implement a brand development strategy, with a focus on strengthening independent innovation and enhancing the brand's position in the global value chain[110]. - The company is actively pursuing market expansion strategies, targeting new geographic regions to drive growth[124]. - The company is exploring potential mergers and acquisitions to strengthen its market position, with a budget of 500 million RMB allocated for this purpose[126]. Risk Management - The company faces risks from market competition and potential product substitution, emphasizing the need for ongoing R&D investment to maintain technological advantages[113]. - Fluctuations in raw material prices, particularly for starch and sugar, could significantly impact product costs and profit margins[113]. - The company is exposed to exchange rate risks due to its reliance on USD for export settlements, which may affect financial performance[114]. - International trade tensions, particularly between the US and China, pose risks to the company's competitiveness in overseas markets[114].

Group 1: Ninebot Company (689009) - The company reported a strong performance in Q1 2025, with revenue of 5.112 billion yuan, a year-on-year increase of 99.5%, and a net profit of 456 million yuan, up 236.2% year-on-year [10] - The forecast for net profit for 2025-2027 has been raised to 1.898 billion, 2.700 billion, and 3.600 billion yuan respectively, reflecting growth rates of 75.1%, 42.2%, and 33.3% [10] - The current market valuation corresponds to a PE ratio of 24X, 17X, and 13X for 2025, 2026, and 2027 respectively, maintaining a "buy" rating [10] Group 2: Kweichow Moutai (600519) - The company achieved a revenue of 43.56 billion yuan in Q1 2025, a year-on-year increase of 9.7%, with a net profit margin of 52.2% [15][13] - The forecast for net profit for 2025-2027 is set at 93.96 billion, 99.14 billion, and 104.71 billion yuan, with growth rates of 9.0%, 5.5%, and 5.6% respectively [11][12] - The company maintains a strong brand presence and cash flow quality, with a current PE ratio of 21X, 20X, and 19X for the respective years [12][13] Group 3: Caibai Co., Ltd. (605599) - The company reported a net profit forecast for 2025-2027 of 804 million, 877 million, and 949 million yuan, with corresponding PE ratios of 13, 12, and 11 [19] - The increase in gold prices has driven demand for investment products, leading to an upward revision of profit forecasts [19] - The company continues to expand its direct store network and enhance its online sales channels, achieving significant growth in e-commerce sales [16][19] Group 4: Bull Group (603195) - The company reported a revenue of 16.831 billion yuan in 2024, a year-on-year increase of 7.2%, and a net profit of 4.272 billion yuan, up 10.4% [18] - The forecast for net profit for 2025-2027 has been adjusted to 8.04 billion, 8.77 billion, and 9.49 billion yuan, maintaining a "buy" rating [19] - The company is focusing on channel expansion and brand recognition to drive long-term sustainable growth [19] Group 5: Shanxi Fenjiu (600809) - The company achieved a revenue of 36.011 billion yuan in 2024, a year-on-year increase of 12.79%, with a net profit of 12.243 billion yuan, up 17.29% [21] - The forecast for net profit for 2025-2027 is set at 12.99 billion, 14.02 billion, and 15.29 billion yuan, with growth rates of 6.1%, 7.9%, and 9.1% respectively [21] - The company maintains a strong market presence with a diversified product range and solid management capabilities [21] Group 6: Yili Group (600887) - The company reported a total revenue of 115.78 billion yuan in 2024, a year-on-year decrease of 8.24%, with a net profit of 8.453 billion yuan, down 18.94% [26] - The forecast for net profit for 2025-2027 is set at 11.377 billion, 12.138 billion, and 12.815 billion yuan, reflecting a growth rate of 35%, 7%, and 6% respectively [28] - The company continues to focus on high-end product penetration and market share expansion in the dairy sector [28]

证券代码：605016 证券简称：百龙创园 公告编号：2025-014 山东百龙创园生物科技股份有限公司 关于续聘会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●拟聘任的会计师事务所名称：致同会计师事务所（特殊普通合伙）。 一、拟续聘会计师事务所的基本情况 （一）机构信息 1、基本信息 会计师事务所名称：致同会计师事务所（特殊普通合伙）（以下简称"致同 所"） 3、业务规模 致同所 2023 年度业务收入 27.03 亿元，其中审计业务收入 22.05 亿元，证 券业务收入 5.02 亿元。2023 年年报上市公司审计客户 257 家，主要行业包括制 造业、信息传输、软件和信息技术服务业、批发和零售业、电力、热力、燃气及 水生产供应业、交通运输、仓储和邮政业，收费总额 3.55 亿元；2023 年年报挂 牌公司客户 163 家，审计收费 3,529.17 万元。 4、投资者保护能力 1 成立日期：1981 年【工商登记：2011 年 12 月 22 日】 注册地址：北京市朝阳区建国门 ...

山东百龙创园生物科技股份有限公司 2024 年度会计师事务所履职情况评估报告及 审计委员会履行监督职责情况报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理准则》 《国有企业、上市公司选聘会计师事务所管理办法》《上海证券交易所上市公司自律 监管指引第 1 号——规范运作》和《公司章程》等规定和要求，董事会审计委员会本 着勤勉尽责的原则，恪尽职守，认真履职。现将董事会审计委员会对会计师事务所履 行监督职责的情况汇报如下： 一、2024 年年审会计师事务所基本情况 （一）会计师事务所基本情况 1．基本信息 会计师事务所名称：致同会计师事务所（特殊普通合伙）（以下简称"致同所"） 成立日期：1981 年【工商登记：2011 年 12 月 22 日】 注册地址：北京市朝阳区建国门外大街 22 号赛特广场五层 首席合伙人：李惠琦 执业证书颁发单位及序号：北京市财政局 NO 0014469 致同所 2023 年度业务收入 27.03 亿元，其中审计业务收入 22.05 亿元，证券业 务收入 5.02 亿元。2023 年年报上市公司审计客户 257 家，主要行业包括制造业、信 息传输、软件和信息技术服 ...

关于提请股东大会授权董事会决定 2025 年半年度及 三季度利润分配的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 证券代码：605016 证券简称：百龙创园 公告编号：2025-017 山东百龙创园生物科技股份有限公司 山东百龙创园生物科技股份有限公司（下称"公司"）第三届董事会第十五 次会议审议通过了《关于提请股东大会授权董事会决定 2025 年半年度及三季度 利润分配的议案》。 为加大投资者回报力度，分享经营成果，提振投资者的持股信心，公司决定 根据《上市公司监管指引第 3 号——上市公司现金分红》《上海证券交易所股票 上市规则》《公司章程》等有关规定，提请股东大会授权董事会全权办理半年度 及三季度利润分配相关事宜。现金分红总额不超过公司 2025 年半年度及三季度 实现的归属于上市公司股东净利润的 30%，是否实施中期利润分配及具体分配金 额等具体分配方案由董事会根据 2025 年半年度及三季度业绩和公司资金需求状 况确定。 特此公告。 山东百龙创园生物科技股份有限公司董事会 2025 年 4 月 30 ...

二〇二五年四月 山东百龙创园生物科技股份有限公司 2024 年度环境、社会及公司治理 （ESG）工作报告 | 关于我们 | | 2 | | --- | --- | --- | | 关于本报告 | | 2 | | 环境信息 | | 3 | | 社会信息 | | 6 | | 产品责任 | | 10 | | 隐私与信息安全 | | 13 | | 供应链责任 | | 13 | | 社区公益 | | 14 | | 治理信息 | | 14 | | 社会责任管理 | | 14 | | 公司治理 | | 17 | | 投资者关系 | | 18 | | 风险与内控 | | 19 | | 商业道德与反腐败 | | 20 | | 党建工作 | | 21 | 山东百龙创园生物科技股份有限公司 2024 年度环境、社会及公司治理（ESG）工作报告 关于我们 山东百龙创园生物科技股份有限公司（以下简称"公司"或"百龙创园"） 成立于 2005 年 12 月 30 日，公司于 2021 年 4 月 21 日在上海证券交易所首次公 开发行 A 股上市。股票简称：百龙创园，股票代码：605016，公司总股本 32,308.64 万股。2024 ...